Clinical Trials Directory

Trials / Completed

CompletedNCT01993004

Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
Rutgers, The State University of New Jersey · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.

Detailed description

MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis. The expression of microRNA will be analysed in cell subsets separated from peripheral blood mononuclear cells.

Conditions

Timeline

Start date
2013-07-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2013-11-25
Last updated
2016-04-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01993004. Inclusion in this directory is not an endorsement.